3) ruconest Riedl:\
The primary outcome in the Phase II RCT (Riedl 2017) was the total number of subject-reported HAE attacks during the treatment periods.64 Both the once-weekly and twice-weekly intravenous doses of Ruconest resulted in significant reductions in the rate of HAE attacks compared to placebo (4.4 and 2.7, respectively vs. 7.2; both p < 0.0004).64 The mean reduction in HAE attack rate versus placebo was estimated to be 63% for the twice-weekly group, and 35% for the once-weekly group. In total, 74% of patients in the twice-weekly group (95% CI: 56.8-86.3), and 42% of patients in the once-weekly group (95% CI: 26.4-59.2) achieved a 50% reduction in HAE attacks versus placebo.64
4)Lana blz 25 en 26
The primary outcome in the HELP trial was the total number of investigator-confirmed HAE attacks over 26 weeks.37 The number of investigator-confirmed HAE attacks requiring acute treatment, and the number of moderate or severe investigator-confirmed HAE attacks were reported as secondary outcomes. The total mean HAE attack rate was significantly lower for all patients on all three lanadelumab doses (300 mg q2wks, 300 mg q4wks, and 150 mg q4wks) when compared to those on placebo (0.26, 0.53, and 0.48 attacks per month vs. 1.97 attacks per month; all p < 0.001), resulting in a 73% to 87% reduction in the frequency of HAE attacks (see Table 3.6).37 More patients on lanadelumab prophylaxis were attack-free over the duration of the study (39%-44%) compared to those on placebo (2%).37 In addition, patients on all three lanadelumab doses showed a statistically-significantly lower rate of attacks requiring acute treatment compared to those on placebo (0.21, 0.42, and 0.31 attacks per month vs. 1.64 attacks per month; all p < 0.001), resulting in 74% to 87% reduction in the frequency of HAE attacks requiring rescue medication (see Table 3.6).37 Similarly, significant differences in favor of lanadelumab prophylaxis compared to placebo were observed in the rates of investigator-confirmed moderate or severe HAE attacks (see Table 3.6).
reductie aanvallen dus hoger dan ruconest, maar lichtere gevallen.....
Kortom: 21 september moet je echt afwachten, ook Kempen. Wel legt lana de lat hoog voor Ruconest.
Maar vergelijken kan dus eigenlijk niet!!